Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 07-011 | Other Identifier | Fox Chase Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline. Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression, immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase activity by ELISA and α_2-antiplasmin converting enzyme.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| protein expression analysis | Genetic | |||
| western blotting | Genetic | |||
| immunohistochemistry staining method | Other | |||
| immunologic technique | Other | |||
| laboratory biomarker analysis | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression | Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of exploiting the circulatory compartment to identify surrogates of tumor FAP | Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence | |
| Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme |
Not provided
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Not provided
Surgury patients scheduled to undergo a resection or exploration of their pancreatic tumor
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven Cohen, MD | Fox Chase Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fox Chase Cancer Center - Philadelphia | Philadelphia | Pennsylvania | 19111-2497 | United States |
Not provided
Not provided
Not provided
Not provided
peripheral blood sample
| Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence |
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D004066 | Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015153 | Blotting, Western |
| D007150 | Immunohistochemistry |
| D007158 | Immunologic Techniques |
| ID | Term |
|---|---|
| D004586 | Electrophoresis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
| D055664 | Electrochemical Techniques |
| D015151 | Immunoblotting |
| D007118 | Immunoassay |
| D015336 | Molecular Probe Techniques |
| D006651 | Histocytochemistry |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D006652 | Histological Techniques |
Not provided
Not provided